Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
about
Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cellsThe clinical application of mesenchymal stromal cells in hematopoietic stem cell transplantationMesenchymal Stem/Stromal Cells in Stromal Evolution and Cancer ProgressionMesenchymal stem cells and immunomodulation: current status and future prospectsOptimization of pre-transplantation conditions to enhance the efficacy of mesenchymal stem cellsCurrent and emerging strategies for the prevention of graft-versus-host diseaseHuman mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trialsRecent Developments in Cellular Immunotherapy for HSCT-Associated ComplicationsWharton's Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host DiseaseBone marrow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone marrow microenvironment.Mesenchymal stem cell therapy and acute graft-versus-host disease: a review.Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices.Recent advances in the management of graft-versus-host disease.Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials.Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation.Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of ageKinetics of IL-7 and IL-15 levels after allogeneic peripheral blood stem cell transplantation following nonmyeloablative conditioningIdentification of appropriate reference genes for human mesenchymal cells during expansion and differentiation.Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation.Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation.Mesenchymal stem cells are enriched in head neck squamous cell carcinoma, correlates with tumour size and inhibit T-cell proliferation.Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases.Could cancer and infection be adverse effects of mesenchymal stromal cell therapy?Potential benefits of allogeneic bone marrow mesenchymal stem cells for wound healing.No Synergistic Effect of Cotransplantation of MSC and Ex Vivo TPO-Expanded CD34(+) Cord Blood Cells on Platelet Recovery and Bone Marrow Engraftment in NOD SCID Mice.Mouse bone marrow-derived mesenchymal stem cells inhibit leukemia/lymphoma cell proliferation in vitro and in a mouse model of allogeneic bone marrow transplant.Mesenchymal stromal cells: a new tool against graft-versus-host disease?Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host diseasePotential functional applications of extracellular vesicles: a report by the NIH Common Fund Extracellular RNA Communication ConsortiumNeuroprotection and immunomodulation by xenografted human mesenchymal stem cells following spinal cord ventral root avulsionDirect Comparison of Wharton's Jelly and Bone Marrow-Derived Mesenchymal Stromal Cells to Enhance Engraftment of Cord Blood CD34(+) TransplantsPrevention of graft-vs.-host diseaseExogenous endothelial cells as accelerators of hematopoietic reconstitution.Clinical-scale expansion of mesenchymal stromal cells: a large banking experience.Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized studyPromising cellular therapeutics for prevention or management of graft-versus-host disease (a review).Mesenchymal stem cells in tissue repairAssessment of immunosuppressive activity of human mesenchymal stem cells using murine antigen specific CD4 and CD8 T cells in vitro.Mesenchymal stem cells provide prophylaxis against acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: A meta-analysis of animal modelsConcise review: hitting the right spot with mesenchymal stromal cells.
P2860
Q21245484-0E56659F-A8E5-4595-BBC0-5FEC4FDF7D8FQ26748595-1664CA55-05CA-43BC-AE4B-FEDB0EAF5F0EQ26770002-37F05921-3FD8-4504-A2D8-980DF2F1F3AAQ26770191-FC5F320A-14A8-4AD6-B18B-09B47C921850Q27015774-E614FA99-8C77-4520-ADA6-FF236E0BC7BDQ27016541-FE3C2D7A-B9BB-4236-9122-5F91951AD5BEQ28071916-C0BBD3BA-AC04-4AAC-A83A-8AE9F8C38E22Q28079823-C021050B-3F44-4631-8CAC-31504CD83EA3Q28083027-DAB09176-01FD-4BF6-96F3-A17E740AB59DQ34058486-B8527579-6670-4BC9-B600-65CC7C975D41Q34294935-023C4240-3E79-479C-9E91-ED1F25BF30BBQ34422955-C26D21FE-8C38-45E2-8509-40AE230A4B93Q34428890-DB84AFB2-F67C-4048-B117-C31FD3729100Q34469147-D307312D-E9D2-4B92-B178-57AA1DD55A93Q34520475-FD54318B-F827-4E82-B8C3-845BA2282B54Q34543056-35C87F3C-7BB9-4318-91EA-3591A3A0873BQ34598248-C135C39F-83DE-4ACF-8BF0-778D35FABB4BQ34984540-4D1A5ADD-EBFE-4F29-9B10-ABABBD5B7CE8Q35007600-746D22E0-C81D-4B59-8D99-C5F4ADE714BAQ35022269-7E11F373-ED92-480A-B703-5ABD8B88A8B3Q35098364-9CF91F8C-E3A1-437E-AF41-270331B293F9Q35203695-1EE4149E-C900-4CA5-9734-E7C0181B09C4Q35205677-77A980D9-5F48-4990-B7A2-950389CDED40Q35285073-78271016-75F7-4ECF-9DB2-E238E7B1AA87Q35797189-6578F490-BD18-40E9-986E-EAAE5BAC3677Q35827639-F226A5E1-D724-4D57-9152-2078F6915388Q35848391-61F3DEDB-6D05-4A61-A7DE-F791682C2E96Q35995245-69503425-7CE3-4572-824A-143034049C93Q36006436-9AFA15FD-E148-4AAC-8511-A5F6AB0BC934Q36262326-01B9A0BB-9C09-4FDF-B8BA-1E17D19F4635Q36297922-9267D15C-BE66-42FD-A2FE-6A366D4BEE7AQ36431047-DE73E84D-2515-4574-AD17-F4C326915D7BQ36527110-0159D07B-7ABF-4920-930C-A32159ED4470Q36923358-C873640C-E4B3-4AE2-96A5-9D1F13586CB3Q37022116-82BD22FE-1385-4DD1-A179-3AAC8A885199Q37140023-9CC6F47B-2D32-4F5B-981B-BB91A4F857EFQ37142817-0FD8F1F1-2657-4305-A452-7C24AB9609EEQ37372319-2A6F54DB-0627-450C-81D9-F75F08869EF6Q37641684-AEB3C69B-6038-4759-8C53-CE9366633B62Q37769501-7614CD4A-7160-48FF-AA35-1B88984A6F8A
P2860
Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Cotransplantation of mesenchym ...... nonmyeloablative conditioning.
@en
Cotransplantation of mesenchym ...... from graft-versus-host disease
@nl
type
label
Cotransplantation of mesenchym ...... nonmyeloablative conditioning.
@en
Cotransplantation of mesenchym ...... from graft-versus-host disease
@nl
prefLabel
Cotransplantation of mesenchym ...... nonmyeloablative conditioning.
@en
Cotransplantation of mesenchym ...... from graft-versus-host disease
@nl
P2093
P1476
Cotransplantation of mesenchym ...... nonmyeloablative conditioning.
@en
P2093
André Gothot
Chantal Lechanteur
Etienne Baudoux
Evelyne Willems
France Bruck
Frédéric Baron
Georges Fillet
Jean-François Vanbellinghen
Kaoutar Hafraoui
Laurence Seidel
P304
P356
10.1016/J.BBMT.2010.01.011
P577
2010-01-28T00:00:00Z